-
2012.12.04
- Noven Pharmaceuticals, Inc. press release : Noven acquires commercial rights to Minivelle™ (estradiol transdermal system)
-
2012.11.13
- Notice of Filing of New Drug Application for Approval to Manufacture and Sell Cancer Pain Drug KW-2246
-
2012.11.13
- Noven Pharmaceuticals, Inc. press release : FDA accepts Noven’s NDA for an investigational nonhormonal therapy for menopausal vasomotor symptoms
-
2012.10.10
- FY02/2013 Q2 Results Earnings Release Presentation
-
2012.10.04
- Noven Pharmaceuticals, Inc. press release : Noven annouces positive Phase 3 data results for investigational low-dose nonhormonal therapy for the treatment of vasomotor symptoms associated with menopause
-
2012.10.03
- Noven Pharmaceuticals, Inc. press release : Noven annouces commencement of Phase 2 study of investigational d-Amphetamine Transdermal System for ADHD(199
-
2012.09.26
- Notice of Revision Financial Forecast
-
2012.08.30
- Noven Pharmaceuticals, Inc. press release : Noven submits New Drug Application for investigational non-hormonal therapy for menopausal vasomotor symptoms
-
2012.08.02
- Notification regarding Acquisition of Kurumin Mark Certification Based on the Law for Measures to Support the Development of the Next Generation
-
2012.07.10
- FY02/2013 Q1 Results Earnings Release Presentation
-
2012.07.02
- Noven Pharmaceuticals, Inc. press release : Noven provides update on Lidoderm® patent challenge (Paragraph IV Litigation Initiated by Patent Holders)
-
2012.07.02
- Notice of Personnel Changes
-
2012.07.02
- Announcement of marketing of “Fentanyl 3-day tape ‘HMT’”, a dermally absorbed remedy for persistent cancer pain
-
2012.06.21
- The dispatch of directors to Yutoku Pharmaceutical Ind. Co., Ltd.
-
2012.06.18
- Notice of dissolution and liquidation of subsidiaries (dormant companies)
-
2012.06.12
- Establishment of Joint Venture for OTC Allergy Medications
-
2012.05.24
- Notice of Personnel Changes
-
2012.05.18
- Application filed for Overactive Bladder Drug HOB-294 (Oxybutynin Hydrochloride, Transdermal Therapeutic Formulation)
-
2012.04.25
- Results of a Japanese Phase III Clinical Study of HTU-520 (Terbinafine Hydrochloride Patch): A Therapeutic Agent for Tinea Unguium
-
2012.04.10
- FY02/2012 Q4 Results Earnings Release Presentation
-
2012.04.03
- Announcement on Launching the Topical Analgesic Patch “SALONPAS” in Chinese market
-
2012.03.28
- Notice of Appointment of Executive Officer
-
2012.03.21
- Noven Pharmaceuticals, Inc. press release : Noven completes Phase3 clinical program for investigational non-hormonal therapy for menopausal vasomotor symptoms
-
2012.01.17
- Regarding the Capital and Business Partnership with Yutoku Pharmaceutical lnd. Co., Ltd.
-
2012.01.12
- FY02/2012 Q3 Results Earnings Release Presentation
